Ashram Road, Ahmedabad-380 009. Phone: 079 - 2658 0549, 2658 5814

Fax: 079 - 2658 1236

E mail: mukesh@mmsco.in / contact@mmsco.in

Website: www.mmsco.in



INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF DIALFORHEALTH INDIA LIMITED

Report on the Standalone Financial Statements

We have audited the accompanying Standalone financial statements of **DIALFORHEALTH INDIA LIMITED** ("the Company"), which comprise the Balance Sheet as at 31st. March, 2015, the Statement of Profit and Loss and the Cash Flow Statement for the year then ended and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible or the matters in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes the maintenance of adequate accounting records in accordance with the provision of the Act for safeguarding of the assets of the Company and for preventing and detecting the frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of internal financial control, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility


Our responsibility is to express an opinion on these Standalone financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidences about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Ashram Road, Ahmedabad-380 009.

Phone . 079 - 2658 0549, 2658 5814

Fax: 079 - 2658 1236

E mail: mukesh@mmsco.in / contact@mmsco.in

Website: www.mmsco.in



Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- (a) in the case of the Balance Sheet, of the state of affairs of the Company as at 31st March, 2015;
- (b) in the case of the Statement of Profit and Loss, of the profit for the year ended on that date; and
- (c) in the case of the Cash Flow Statement, of the cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

- 1. As required by the Companies (Auditor's Report) Order, 2015 ("the Order") issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Act, we give in the Annexure a statement on the matters specified in paragraphs 3 and 4 of the Order.
- 2. As required by Section 143 (3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;
 - (e) On the basis of the written representations received from the directors as on 31st March, 2015 and taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2015 from being appointed as a director in terms of section 164(2) of the Act.
 - (f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - a. The Company does not have any pending litigations which would impact its financial position.
 - The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - c. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For MUKESH M. SHAH & CO.

Chartered Accountants

Firm Registration No.: 106625

C.S.Shah Chandresh S. Shah

D .

Partner

Membership No.: 042132

Place: Ahmedabad

Date: 12/05/2015

Ashram Road, Ahmedabad-380 009. Phone : 079 - 2658 0549, 2658 5814

Fax: 079 - 2658 1236

E mail: mukesh@mmsco.in / contact@mmsco.in

Website: www.mmsco.in



AHMEDABAD - MUMBAI - BANGALORE

ANNEXURE REFERRED TO IN THE INDEPENDENT AUDITORS' REPORT OF EVEN DATE TO THE MEMBERS OF DIALFORHEALTH INDIA LIMITED ON THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2015.

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, we report that:

- 1) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
 - (b) Some of the fixed assets were physically verified during the year by the management in accordance with programme of verification, which in our opinion provides for physical verification of all the fixed assets at reasonable intervals. According to the information and explanations given to us no material discrepancies were noticed on such verification. In our opinion, the frequency of verification of the fixed assets is reasonable having regard to the size of the Company and the nature of its assets.
- 2) (a) The inventories have been physically verified by the management during the year.
 - (b) In our opinion, the procedures for the physical verification of inventory followed by management are reasonable and adequate in relation to the size of the company and the nature of its business.
 - (c) In our opinion and according to the information and explanation given to us, the company has maintained proper records of inventory. No material discrepancies were noticed on physical verification of inventory.
- 3) In respect of the an unsecured loan granted by the Company to a company covered in the register maintained under Section 189 of the Companies Act, 2013:
 - (a) The principal amount is repayable over a period of three years, while the interest is payable annually.
 - (b) In respect of the said loan and interest thereon, there is no overdue amount.
- 4) In our opinion, there is an adequate internal control system commensurate with the size of the Company and the nature of its business for the purchase of inventory and fixed assets and for the sale of goods and services. During the course of our audit, no major weakness has been noticed in the internal control system in respect of these areas.
- 5) The Company has not accepted any deposits from the Public within the meaning of the provisions of section 73 to 76 or any other relevant provisions of the Companies Act, 2013 and the rules framed thereunder. Further, we are informed that no order has been passed by the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any other Court or Tribunal.
- 6) In absence of any manufacturing activities carried out by the company, the requirement of maintenance of cost records under sub-section 1 of section 148 of the Companies Act, 2013 are not applicable to the Company during the year under audit.
- 7) (a) According to the information and explanations given to us and on the basis of our examination of the books of account, the company has been regular in depositing undisputed statutory dues including Provident Fund, Employees' State Insurance, Income-tax, Sales-tax, Service tax, Value added Tax, and any other material statutory dues during the year with the appropriates authorities. Moreover, as at 31st March, 2015, there are no such undisputed dues payable for a period of more than six months from the date they became payable.

Ashram Road, Ahmedabad-380 009. Phone: 079 - 2658 0549, 2658 5814

Fax: 079 - 2658 1236

E mail: mukesh@mmsco.in / contact@mmsco.in

Website: www.mmsco.in



AHMEDABAD - MUMBAI - BANGALORE

- (b) According to the information and explanations given to us, there is no dues under dispute for Income tax, Sales tax, Excise duty and Service tax and other material statutory dues as at 31st March, 2015.
- According to the information and explanations given to us, there is no amount required to be (c) transferred to Investor Education and Protection Fund in accordance with the relevant provisions of the Companies Act, 1956 and rules made thereunder.
- The accumulated losses at the end of the financial year has not exceeded fifty per cent of the net 8) worth of the Company and has not incurred cash losses during the financial year and during the immediately preceding financial year.
- 9) As per the information and explanation given to us, the Company has not defaulted in repayment of dues to any banks or financial institutions or debenture holders during the year.
- In our opinion and according to the information and explanations given to us, the Company has not given any guarantees for loans taken by any other companies; hence question of reporting under clause 3(x) of the order does not arise.
- 11) The Company has not availed any term loans during the year, hence, question of reporting under clause 3(xi) of the order does not arise.
- To the best of our knowledge and based on information and explanations received from the management, no fraud on or by the Company has been noticed or reported during the period covered by our audit.

H. K. HOUSE

For MUKESH M. SHAH & CO.

Chartered Accountants

Firm Registration No.: 106625W

CSSCO Chandresh S. Shah

Partner

Membership No.: 042132

Place: Ahmedabad

Date: 12/05/2015

	Note	ote INR - Thousands	
Particulars	No.	As at March 31	
		2015	2014
EQUITY AND LIABILITIES:			
Shareholders' Funds:			
Share Capital	1	250,000	250,00
Reserves and Surplus	2	(87,946)	(88,93
		162,054	161,06
Non-Current Liabilities:	į		
Long Term Borrowings	3	124,176	132,17
Other Long Term Liabilities	4	356	35
Long Term Provisions	5	1,299	1,02
	l F	125,831	133,55
Current Liabilities:	1 1		•
Trade Payables	6	923	6,33
Other Current Liabilities	7	1,731	1,50
Short Term Provisions	8	165	
		2,819	7,92
Total		290,704	302,54
ASSETS:	.		
Non-Current Assets:			
Fixed Assets:			
Tangible Assets	9	5,485	10,48
Non Current Investments	10	-	2,77
Long Term Loans and Advances	11	202,521	206,23
		208,006	219,47
Current Assets:			,
Inventories	12	76,241	75,74
Trade Receivables	13	1,689	28
Cash and Bank Balances	14	4,013	6,34
Short Term Loans and Advances	15	711	66
Other Current Assets	16	44	3
		82,698	83,07
Total	l F	290,704	302,54
Significant Accounting Policies	II		
Notes to the Financial Statements	1 to 36		

For Mukesh M. Shah & Co.

Chartered Accountants

Firm Registration Number: 1066257 M. SH4

H. K. HOUSE ASHRAM ROAD,

AHMEDABAD-9.

CSShal

Chandresh S. Shah

Partner

Membership Number: 042132
Ahmedabad, Dated: 12 05 2015

Jayesh K. Patel Urvina

Chief Financial Officer

Urvi-A. Kadakia

Company Secretary

Director - Operation

Dialforhealth India Limited				
Statement of Profit and Loss for the year ended March 31, 2015				
	Note	INR - Thou	usands	
Particulars	No.	Year ended M	larch 31	
		2015	2014	
REVENUE:				
Revenue from Operations:				
Sale of Products	18	137,338	116,5	
Other Operating Revenues	18	693	1,5	
Revenue from Operations		138,031	118,0	
Other Income	19	20,067	17,5	
Total Revenue		158,098	135,6	
EXPENSES:		1		
Purchases of Stock-in-Trade	20	122,499	112,3	
Changes in Inventories of Stock-in-Trade	21	(500)	(12,7	
Employee Benefits Expenses	22	12,120	11,1	
Finance Cost	23	353	2	
Depreciation and Amortisation expenses	9 & 35	1,728	1,7	
Other Expenses	24	13,546	17,6	
Total Expenses		149,746	130,3	
Profit before exceptional & extraordinary items and Tax		8,352	5,2	
Less : Exceptional Items	25	4,275	-	
Profit before Tax		4,077	5,2	
Less: Tax Expense:		,,,,,	3,2	
Deferred Tax	34		_	
Profit for the year	· · · ·	4,077	5,2	
Basic & Diluted Earning per Equity Share [EPS] [in Rupees]	26	0.82	1.0	
Significant Accounting Policies	II	0.02	1.	
Notes to the Financial Statements	1 to 36			

As per our report of even date

For Mukesh M. Shah & Co.

Chartered Accountants

Firm Registration Number

Chandresh S. Shah

Partner

Membership Number: 042132 Ahmedabad, Dated: 12 0 5 2015

H. K. HOUSE ASHRAM ROAD, AHMEDA BAD. 3

For and on behalf of the Board

Chief Financial Officer

Unvi A. Kadakia Company Secretary

Director - Operation

Particulars	INR-Thousa	nd	
	Year ended March 31		
	2015	2014	
A Cash flows from operating activities:			
Profit before Tax	4,0	77 5,231	
Adjustments for:			
Depreciation	1,728	1,761	
Provision for diminution in value of investments	2,775	-	
Provision for doubtful advances	1,500	-	
Loss on sale of assets	66		
Provisions for employee benefits	353	(132	
Total	6,4	1,637	
Operating profit before working capital changes	10,4	6,868	
Adjustments for:			
[Increase]/ Decrease in inventories	(500)	(12,779	
[Increase]/ Decrease in short term advances	(42)	(56	
[Increase]/ Decrease in long term advances	1,547	(200,182	
[Increase]/ Decrease in other current assets	(10)	(6	
[Increase]/ Decrease in other trade receivables	(1,402)	(287	
Increase/ [Decrease] in trade payables	(5,410)	5,772	
Increase/ [Decrease] in other current liabilities	226	531	
Total	(5,5)	(207,007	
Cash generated from operations	4,9	(200,139	
Direct taxes paid [Net of refunds]	6-	15 (429	
Net cash from operating activities	5,5		
B Cash flows from investing activities:			
Sale of fixed Assets	136	_	
Purchase of fixed assets	(16)	(459	
Net cash from investing activities	1:	(459	
C Cash flows from financing activities:	·		
Proceeds from issue of Preference Share Capital	-	200,000	
Proceeds from Long Term Borrowings	-	1,500	
Repayment of Long Term Borrowings	(8,000)		
Net cash from financing activities	(8,00	201,500	
Net increase in cash and cash equivalents	(2,3:	27) 473	
Cash and cash equivalents at the beginning of the year	6,34	5,867	
Cash and cash equivalents at the end of the year	4,0:	6,340	

1 All figures in brackets are outflows.

2 Previous year figures have been regrouped wherever necessary.

3 Cash and cash equivalents at the end [beginning] of the year includes Rs. Nil [Rs. Nil] not available for immediate use.

Jayesh K. Patel

Company Secretary

Chief Financial Officer

As per our report of even date For Mukesh M. Shah & Co.

Chartered Accountants

Firm Registration Number: 106625

Csshort Chandresh S. Shah

Partner

Membership Number: 042132
Ahmedabad, Dated: (2 05 25 5

For and on behalf of the Board

V. K. Sharma

Director

Dialforhealth India Limited

I-Company Overview:

Dialforhealth India Limited [the Company] was incorporated on March 6, 2000. The company's registered office is situated at Zydus Tower, Satellite Cross Roads, Ahmedabad. The principal business of the company is to run retail pharmacy stores across India. The Company's shares are held by Cadila Healthcare Limited and its nominees [Holding Company].

II-Significant Accounting Policies:

1 Basis of Accounting:

The financial statements are prepared under the historical cost convention on the "Accrual Concept" of accountancy in accordance with the accounting principles generally accepted in India and they comply with the Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies [Accounts] Rules, 2014 and other pronouncement issued by the Institute of Chartered Accountants of India [ICAI], to the extent applicable, and with the applicable provisions of the Companies Act, 2013.

2 Use of Estimates:

The preparation of Financial Statements in conformity with the Accounting Standards generally accepted in India requires, the management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as at the date of the financial statements and reported amounts of revenues and expenses for the reporting period while actual results could differ from these estimates. Any revision to accounting estimates is recognised prospectively in current and future periods.

3 Fixed Assets and Depreciation:

- A Fixed Assets are stated at historical cost of acquisition/ construction less accumulated depreciation and impairment loss. Cost [Net of Input tax credit received/ receivable] includes related expenditure and pre-operative & project expenses for the period up to completion of construction/ assets are put to use.
- **B** Depreciation on tangible assets is provided on "straight line method" based on the useful lives as prescribed under Schedule II of the Companies Act, 2013.
- C Depreciation on additions/ disposals of the fixed assets during the reporting period is provided on pro-rata basis according to the period during which assets are put to use.
- **D** Where the actual cost of purchase of an asset is below Rs. 10,000/-, the depreciation is provided @ 100%.

4 Borrowing Costs:

- A Borrowing costs that are directly attributable to the acquisition/ constructions of a qualifying asset are capitalised as part of the cost of such assets, up to the date, the assets are ready for their intended use.
- **B** Other Borrowing costs are recognised as an expense in the period in which they are incurred.

5 Expenditure during construction period:

The expenditure incurred for/ incidental to the establishment of retail shops are shown under "Pre operative and project expenses pending allocation". The said expenditure are allocated to fixed assets upon commencement of operation by the respective retail shop.

6 Investments:

Long term and strategic investments are stated at cost, less any diminution in the value other than temporary.

7 Inventories:

Trading Goods are valued at lower of cost [Net of Input tax credit availed] and net realisable value.

8 Revenue Recognition:

- A Revenue from sale of goods is recognised when significant risk and rewards of ownership of the goods have been passed on to the buver.
- **B** Service income is recognised as per the terms of the contract with the customers when the related services are performed or the agreed milestone are achieved and are net of service tax wherever applicable.
- **C** Interest income is recognised on time proportionate method.
- **D** Revenue in respect of other income is recognised when no significant uncertainty as to its determination or realisation exists.

9 Employee Benefits:

A Defined Contribution Plans:

The Company contributes on a defined contribution basis to Employees' Provident Fund towards post employment benefits, all of which are administered by the respective Government authorities, and has no further obligation beyond making its contribution, which is expensed in the period to which it pertains.

B Defined Benefit Plans:

The gratuity scheme is administered through the Life Insurance Corporation of India [LIC]. The liability for the defined benefit plan of Gratuity is determined on the basis of an actuarial valuation by an independent actuary at the reporting period end, which is calculated using projected unit credit method.

Actuarial gains and losses which comprise experience adjustment and the effect of changes in actuarial assumptions are recognised in the Statement of Profit and Loss.

C Leave Liability:

The employees of the company are entitled to leave as per the leave policy of the company. The liability on account of accumulated leave as on last day of the reporting period is recognised [net of the fair value of plan asset as at the balance sheet date] at present value of the defined obligation at the balance sheet date based on the actuarial valuation carried out by an independent actuary using projected unit credit method.



Dialforhealth India Limited

II - Significant Accounting Policies-Continued:

10 Provision for Bad and Doubtful Debts/ Advances:

Provision is made in accounts for bad and doubtful debts/ advances which in the opinion of the management are considered doubtful of recovery.

11 Taxes on Income:

- A Tax expenses comprise of current and deferred tax.
- **B** Current tax is measured at the amount expected to be paid on the basis of reliefs and deductions available in accordance with the provisions of the Income Tax Act, 1961.
- C Deferred tax reflects the impact of current reporting period timing differences between accounting and taxable income and reversal of timing differences of earlier reporting periods. Deferred tax is measured based on the tax rates and laws that have been enacted or substantively enacted as of the balance sheet date. Deferred tax assets are recognised only to the extent there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised and are reviewed at each balance sheet date.

12 Leases:

Leases are classified as operating leases where the lessor effectively retains substantially all the risks and benefits of the ownership of the leased assets. Operating lease payments are recognised as expenses in the statement of Profit and Loss as on a straight line basis over the lease term.

13 Provisions, Contingent Liabilities and Contingent Assets:

Provision is recognised when the company has a present obligation as a result of past events and it is probable that the outflow of resources will be required to settle the obligation and in respect of which reliable estimates can be made. A disclosure for contingent liability is made when there is a possible obligation, that may, but probably will not require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision/ disclosure is made. Contingent assets are not recognised in the financial statements. Provisions and contingencies are reviewed at each balance sheet date and adjusted to reflect the correct management estimates.



bee: 1-Share Capital: Authorised: 5,000,000 [as at March 31, 2014: 5,000,000] Equity Shares of Rs.10/- each 2,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares of Rs.100/- each 2,000,000 [as at March 31, 2014: 2,000,000] Equity Shares of Rs.10/- each, fully paid-up 2,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares of Rs.100/- each 7,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares of Rs.100/- each 7,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares of Rs.100/- each 7,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares 7,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares 7,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares 7,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares 7,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares 7,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares 8,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares 8,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares 8,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Redeemable Preference Shares 9,000,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Shares and six Non-cumulative March 31, 2014: 2,000,000] 8,000 [as at March 31, 2014: 2,000,000] Six Non-cumulative Shares and six Non-cumulative March 31, 2014; Six Non-cumulative Shares and six Non-cumulative March 31, 2014; Six Non-cumulative Shares and six Non-cumulative March 31, 2014; Six Non-cumulative Shares and six Non-cumulative March 31, 2014; Six Non-cumulative Shares and six Non-cumulative Shares			Dialforhealth India Limited Notes to the Financial Statements	
es 1-Share Capital: Authorised: \$,000,000 [as at March 31, 2014; 5,000,000] Equity Shares of Rs.10/- each 2,000,000 [as at March 31, 2014; 2,000,000] S/k Non-cumulative Redeemable Preference Shares of Rs.100/- each 2,000,000 [as at March 31, 2014; 5,000,000] Equity Shares of Rs.10/- each, fully paid-up 2,000,000 [as at March 31, 2014; 2,000,000] S/k Non-cumulative Redeemable Preference Shares of Rs.100/- each 3,000,000 [as at March 31, 2014; 2,000,000] S/k Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 [as at March 31, 2014; 2,000,000] S/k Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 [as at March 31, 2014; 2,000,000] S/k Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 [as at March 31, 2014; 2,000,000] S/k Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 [as at March 31, 2014; 2,000,000] S/k Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 [as at March 31, 2014; 2,000,000] A there is no change in the number of equity shares as at the beginning and end of the year Number of shares at the beginning of the year Number of shares at the beginning of the year Number of shares at the seginning of the year 1,000,000 All Preference shares shall be ontitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares shall be entitled to rank as regards regardment of capital in the event of distribution of proffits by the company. In case of winding up of the Company, preference shares shall be entitled to rank as regards regardment of capital and dividend up to the commencement of winding up, in proffit to equity shares. P All Equity shares of Rs. 101/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nomines Number of Shares Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as per last Bala	ousands	INR - Thou		
### State Capital: Atthorised: 5,000,000 (as at March 31, 2014; 5,000,000) Equity Shares of Rs.10/- each 2,000,000 (as at March 31, 2014; 2,000,000) State Non-cumulative Redeemable Preference Shares of Rs.100/- each 3,000,000 (as at March 31, 2014; 2,000,000) State Non-cumulative Redeemable Preference Shares of Rs.100/- each 3,000,000 (as at March 31, 2014; 2,000,000) State Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 (as at March 31, 2014; 2,000,000) State Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 (as at March 31, 2014; 2,000,000) State Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 (as at March 31, 2014; 2,000,000) State Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 (as at March 31, 2014; 2,000,000) State Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 (as at March 31, 2014; 2,000,000) State Shares Number of coulty shares at the beginning and at the end of year 1,000,000 (as at March 31, 2014; 2,000,000) States and of year 1,000,000 (as at March 31, 2014; 2,000,000) States and of year 1,000,000 (as at March 31, 2014; 2,000,000) States and of year 1,000,000 (as at March 31, 2014; 2,000,000) States and year of the year 1,000,000 (as at March 31, 2014; 2,000,000) States and year of the year (as a year of year o	arch 31	As at Marc		
Authorised: 5,000,000 (as at March 31, 2014: 5,000,000] Equity Shares of Rs.10/- each 2,000,000 (as at March 31, 2014: 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each 5,000,000 (as at March 31, 2014: 5,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 (as at March 31, 2014: 5,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 (as at March 31, 2014: 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 (as at March 31, 2014: 2,000,000) 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 (as at March 31, 2014: 2,000,000) 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 (as at March 31, 2014: 2,000,000) 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 (as at March 31, 2014: 2,000,000) 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each 1,000,000 (as at March 31, 2014: 5,000,000) 5% Non-cumulative Redeemable Preference Shares 1,000,000 (as at March 31, 2014: 5,000,000) 5% Non-cumulative Redeemable Preference Shares 1,000,000 (as at March 31, 2014: 5,000,000) 6% Non-cumulative Redeemable Preference Shares 1,000,000 (as at March 31, 2014: 5,000,000) 6% Non-cumulative Redeemable Preference Shares 1,000,000 (as at March 31, 2014: 5,000,000 (as at March 31, 2014: 6% Shares and Equity Shares Shares at the beginning and at the end of the year 2,000,000 2,000,000 2,000,000 2,000,000	2014	2015		
5,000,000 [as at March 31, 2014; 5,000,000] Equity Shares of Rs.10/- each 200,000 [as t March 31, 2014; 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each 239,000 Issued, Subscribed and Paid-up: 5,000,000 [as at March 31, 2014; 5,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each, fully paid-up 2,000,000 [as at March 31, 2014; 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each, fully paid-up 2,000,000 [as at March 31, 2014; 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each, fully paid-up 2,000,000 [as at March 31, 2014; 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each, fully paid end of the year. Number of Shares at the beginning and at the end of year 8 The reconciliation of the number of Preference Shares outstanding is as under: Number of Shares at the beginning of the year 9 Number of Shares at the beginning of the year 9 Number of Shares at the end of the year 9 Number of Shares at the end of the year 9 Number of Shares are redeemable on completion of fifth year from the respective date of its issue, May 17, 2015, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall be entitled to rank as repards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees 9 Number of Shares Number of Shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees 9 Number of Shares 9 ks to total share holding 9 G All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited and Its nominees 9 Number of Shares 9 ks to total share holding 9 S-Zesserves and Surplus: 9 Surplus in statement of Profit and Loss: 8 Balance as per last Balance Sheet 19 Less: Addional depreciation upon revision in useful lives of tangible as				
2,000,000 [as at March 31, 2014: 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each Issued, Subscribed and Paid-up: 5,000,000 [as at March 31, 2014: 2,000,000] Equity Shares of Rs.10/- each, fully paid-up 2,000,000 [as at March 31, 2014: 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each 7 Total A There is no change in the number of equity shares as at the beginning and end of the year. Number of equity shares at the beginning and at the end of year 8 The reconcilation of the number of Preference Shares outstanding is as under: Number of shares at the of the year Add: Shares issued during the year Number of shares at the of the year Add: Shares issued during the year Number of shares at the of the year C The Company has equity shares and preference shares. All equity shares rank part passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shares holders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares are redeemable on completion of fifth year from the respective date of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares % to total share holding G All Preference shares of Rs. 1,100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares % to total share holding Add: Profit for the year Balance as per last Belance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year Cadall Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 124,176 124,176 124,176				Auth
Issued, Subscribed and Paid-up: 5,000,000 [as at March 31, 2014: 5,000,000] Equity Shares of Rs.10/- each, fully paid-up 2,000,000 [as at March 31, 2014: 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each Total A There is no change in the number of equity shares as at the beginning and end of the year. Number of equity shares at the beginning and at the end of year B The reconciliation of the number of Preference Shares outstanding is as under: Number of shares at the beginning of the year Add: Shares state did beginning of the year Number of shares at the end of the year C The Company has equity shares and preference shares. All equity shares rank pair passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shares holders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferencial amounts. D All Preference shares shall carry a preferencial right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shareres shall be entitled to proportionate share of winding up of the Company, preference shareres shall be entitled to proportionate share of winding up of the Company, preference shareres shall be entitled to proportionate share of winding up of the Company, preference shareres shall be entitled to proportionate share of winding up of the Company, preference shareres of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominese Number of Shares Number of Shares Number of Shares S to total share holding All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares S to total share holding All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares S to total share holding B 2-Reserves and Surplus: Surplus in statement o	50,	1		
Issued, Subscribed and Paid-up: 5,000,000 [as at March 31, 2014: 5,000,000] Equity Shares of Rs.10/- each, fully paid-up 2,000,000 [as at March 31, 2014: 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each A There is no change in the number of equity shares as at the beginning and end of the year. Number of equity shares at the beginning and at the end of year B The reconciliation of the number of Preference Shares outstanding is as under: Number of shares at the eignining of the year Add: Shares issued during the year Add: Shares issued for year [as a share of the year of shares and year of shares Add of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. Number of Shares So to total share holding G All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nomines Number of Shares So to total share holding E Z-Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets (Refer Note-35) 3,086 4,077 3,086 4,077 4,090,000 2,000,000 2,000,000 2,000,000 3,000 3,000 4,000 4,000 5,000,000 5,000,000 5,000,000 5,000,000	200,			
5,000,000 [as at March 31, 2014: 5,000,000] Equity Shares of Rs.10/- each, fully paid-up 2,000,000 [as t March 31, 2014: 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each Total A There is no change in the number of equity shares as at the beginning and end of the year. Number of equity shares at the beginning and at the end of year B The reconciliation of the number of Preference Shares outstanding is as under: Number of shares at the beginning of the year Add: Shares issued during the year Add: Shares issued during the year Add: Shares state of shares at the dof of the year C The Company has equity shares and preference shares. All equity shares rank pair passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shares share be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares shall be entitled to completion of fifth year from the respective date of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall be entitled to rank as reqorks repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares % to total share holding 5,000,000 2,000,000 2,000,000 2,000,000	250	250,000		
5,000,000 [as at March 31, 2014: 5,000,000] Equity Shares of Rs. 10/- each, fully paid-up 2,000,000 [as at March 31, 2014: 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs. 100/- each 7 Total 3. There is no change in the number of equity shares as at the beginning and end of the year. Number of equity shares at the beginning and at the end of year B. The reconcilation of the number of Preference Shares outstanding is as under: Number of shares at the beginning of the year Add: Shares issued during the year Number of shares at the of the year. Provision for shares at the deal of the year Add: Shares issued during the year and the centre of the year and year an			and Paid-up	Teen
2,000,000 [as at March 31, 2014: 2,000,000] 5% Non-cumulative Redeemable Preference Shares of Rs.100/- each Total A There is no change in the number of equity shares as at the beginning and end of the year. Number of equity shares at the beginning and at the end of year B The reconciliation of the number of Preference Shares outstanding is as under: Number of shares at the beginning of the year Add: Shares issued during the year Number of shares at the beginning of the year C The Company has equity shares and preference shares. All equity shares rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity sharebidders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares are redeemable on completion of fifth year from the respective date of its issue, May 17, 2013, for 1500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares % to total share holding G All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares % to total share holding Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Total S-1-One Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] Total 24-Other Long Term Borrowings: Loans and advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment	50,	50,000	•	
or Rs.100/- each Total A There is no change in the number of equity shares as at the beginning and end of the year. Number of equity shares at the beginning and at the end of year B The reconciliation of the number of Preference Shares outstanding is as under: Number of shares at the beginning of the year Add: Shares issued during the year Number of shares at the end of the year Number of shares at the end of the year Number of shares at the end of the year Number of shares at the end of the year Add: Shares issued during the year C The Company has equity shares and preference shares. All equity shares rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares are redeemable on completion of fifth year from the respective date of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference sharesholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares Number of Shares Number of Shares % to total share holding S 2.Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last flalance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year Total S 2.400,000 100% S 2.Reserves and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limi	200			
A There is no change in the number of equity shares as at the beginning and end of the year. Number of equity shares at the beginning and at the end of year B The reconciliation of the number of Preference Shares outstanding is as under: Number of shares at the beginning of the year Add: Shares issued during the year Number of shares at the beginning of the year C The Company has equity shares and preference shares. All equity shares rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares are redeemable on completion of fifth year from the respective date of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares Number of Shares Number of Shares Number of Shares Sto total share holding All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees **Statement of Profit and Loss:** Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Total **Statement of Profit and Loss:* Balance as at the end of the year Total **Statement of Profit and Loss:* Balance as at the end of the year Total **Statement of Profit and Loss:* Balance as at the end of the year (87,946) (87,946) (87,946) (87,946) (87,946) (87,946) (87,946) (87,946) (87,946) (87,946) (87,946) (87,946) (87,946)	200	300,000		
A There is no change in the number of equity shares as at the beginning and end of the year. Number of equity shares at the beginning and at the end of year B The reconcilation of the number of Preference Shares outstanding is as under: Number of shares at the beginning of the year Add: Shares issued during the year Number of shares at the end of the year Number of shares at the end of the year Number of shares at the end of the year Number of shares at the end of the year Number of shares at the end of the year Number of shares and preference shares. All equity shares rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares hall be entitled to proportionate share of their holding in the assets remained after distribution of profits by the company. In case of winding up of the Company, preference shares shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nomines Number of Shares % to total share holding G All Preference shares share holding G All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares % to total share holding S: 2-Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] 3.086 Add: Profit for the year Balance as at the end of the year Balance as a	250	250,000		Tota
Number of equity shares at the beginning and at the end of year Number of shares at the beginning of the year Add: Shares issued during the year Number of shares at the end of the year Number of shares at the end of the year Or The Company has equity shares and preference shares. All equity shares rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares are redeemable on completion of fifth year from the respective date of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shareholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 100f- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares % to total share holding 6 All Preference shares of Rs. 100f- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares Salpius in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] 3,086 Add: Profit for the year Balance as at the end of the year Total [*] Details of Loans and Advances from Related Parties [Unsecured] [*] Total [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 124,176 124,176 124,176 124,176 124,176 125-Long Term Long Term Liabilities: Others [Unsecured] Frowi	1		nge in the number of equity shares as at the beginning and end of the year.	Α
B The reconcilation of the number of Preference Shares outstanding is as under: Number of shares at the beginning of the year Add: Shares issued during the year Number of shares at the end of the year C The Company has equity shares and preference shares. All equity shares rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares share redeemable on completion of fifth year from the respective date of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shares for fishing the entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares % to total share holding G All Preference shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares % to total share holding 2.000,000 100% 2.2-Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] 3.086 Add: Profit for the year Balance as at the end of the year Total 124,176 [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company	5,000	5,000,000		
Number of shares at the beginning of the year Add: Shares issued during the year Number of shares at the end of the year C The Company has equity shares and preference shares. All equity shares rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. All Preference shares redeemable on completion of fifth year from the respective date of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shareholders shall be entitled to rank as regards repayment of capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shareholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares % to total share holding G All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares % to total share holding 100% 2.000,000 100% 2.2	1		n of the number of Preference Shares outstanding is as under:	В
Add: Shares issued during the year Number of shares at the end of the year C The Company has equity shares and preference shares. All equity shares rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity sharesholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares are redeemable on completion of fifth year from the respective date of its Issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference sharesholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year Total [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 124,176 134-176 356 Total 15-Long Term Provisions: Provision for Employee Benefits 1,299		2,000,000		
C The Company has equity shares and preference shares. All equity shares rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares are redeemable on completion of fifth year from the respective date of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shareholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominues Number of Shares Number of S	2,000		ied during the year	
C The Company has equity shares and preference shares. All equity shares rank pari passu and carry equal rights with respect to voting and dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares are redeemable on completion of fifth year from the respective date of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shareholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nomininees Number of Shares Number of	2,000	2,000,000	es at the end of the year	
equity shareholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts. D All Preference shares are redeemable on completion of fifth year from the respective date of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference sharesholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares % to total share holding G All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares % to total share holding 2,000,000 100% 22-Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] 3,086 Add: Profit for the year Balance as at the end of the year Balance as at the end of the year Total [*] Details of Loans and Advances from Related Parties [Unsecured] [*] 124,176 [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 124,176 346 356 Total 5-Long Term Liabilities: Others [Unsecured] 759 760 760 760 760 760 760 760 76			* · · · · · · · · · · · · · · · · · · ·	С
after distribution of all preferential amounts. D All Preference shares are redeemable on completion of fifth year from the respective date of its issue, May 17, 2013, for 1, 500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shareholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares Number of Shares Number of Shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares Number of Shares Verono,000 100% 100% 2-Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year 104,977 Balance as at the end of the year Balance as at the end of the year 104,176 104,176 104,176 105,104 1124,176 1124,176 1124,176 1124,176 1124,176 1124,176 1124,176 1124,176 1124,176 1124,176 1124,176 1124,176			respect to voting and dividend. In the event of liquidation of the Company, the	
D All Preference shares are redeemable on completion of fifth year from the respective date of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shareholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year Balance as at the end of the year Total 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] Total 124,176 124,176 124,176 124,176 136 136 136 156 157 107 107 107 108 109 109 109 109 109 109 109	i		lers shall be entitled to proportionate share of their holding in the assets remained	
date of its issue, May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares. E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shareholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares Number of Sha			of all preferential amounts.	
E The Preference shares shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company. In case of winding up of the Company, preference shareholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares % to total share holding G All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares % to total share holding 100% **Serves and Surplus** Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year Balance as at the end of the year S1-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] Total 3-Long Term Borrowings: Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 124,176 124,176 Total **Cother Long Term Liabilities: Others [Unsecured] **Selong Term Provisions: Provision for Employee Benefits 1,299			nares are redeemable on completion of fifth year from the respective	D
in the event of distribution of profits by the company. In case of winding up of the Company, preference shareholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares Number of Shar			May 17, 2013, for 1,500,000 shares and August 1, 2013 for 500,000 shares.	
preference shareholders shall be entitled to rank as regards repayment of capital and dividend up to the commencement of winding up, in priority to equity shares. F. All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares			shares shall carry a preferential right with respect to dividend on the paid up capital	Е
the commencement of winding up, in priority to equity shares. F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares 2,000,000 100%			listribution of profits by the company. In case of winding up of the Company,	
F All Equity shares of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and its nominees Number of Shares % to total share holding G All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares % to total share holding 2,000,000 100% i 2-Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year (87,946) Total i 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] Total 2,4,176 Total 2,4,176 124,176 124,176 1-24,176				
its nominees Number of Shares Number of Shares Number of Shares holding G All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares % to total share holding 2,000,000 100% 22-Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] 3,086 Add: Profit for the year Balance as at the end of the year (87,946) 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] Total 2,4,176 124,176 124,176 124,176 124,176 124,176 124,176 1356 Total S-Long Term Liabilities: Chers [Unsecured] Total S-Long Term Liabilities: Chers [Unsecured] Total 15-Long Term Provisions: Frovision for Employee Benefits			ent of winding up, in priority to equity shares.	
Number of Shares % to total share holding G All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares % to total share holding % to total share holding 2,000,000 100% 22-Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] 3,086 Add: Profit for the year Balance as at the end of the year (87,946) 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] 124,176 124,176 124,176 124,176 124,176 124,176 124,176 124,176 124,176 124,176 125-Long Term Liabilities: Others [Unsecured] Total 5-Long Term Provisions: Provision for Employee Benefits			of Rs. 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited and	F
% to total share holding G All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares % to total share holding 2,000,000 % to total share holding 2-2,000,000 100% 2-Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year (87,946) 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] 124,176 [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 124,176 2-Others [Unsecured] 356 356 356 356 357 358			The state of the s	
G All Preference shares of Rs. 100/- each, fully paid held by Holding Company, Cadila Healthcare Limited Number of Shares % to total share holding 2,000,000 100% 100% 100% 100% 100% 100% 1	5,000	5,000,000		
Number of Shares % to total share holding 2,000,000 % to total share holding 2-Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] 3,086 Add: Profit for the year 4,077 Balance as at the end of the year (87,946) Total 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] 124,176 Total 124,176 [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 124,176 124,176 124,176 124,176 124,176 124,176 124,176 124,176 124,176 124,176 124,176 124,176 124,176	1	100%		
% to total share holding 100% 2-Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year (87,946) Total 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] Total [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 124,176 24-Other Long Term Liabilities: Others [Unsecured] Total 356 Total 356 Total 1-299				G
: 2-Reserves and Surplus: Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year Balance as at the end of the year (87,946) Total 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] Total [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 124,176 24-Other Long Term Liabilities: Others [Unsecured] Total 356 Total 356 Total 1-299	2,000	1 13		
Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year (87,946) Total 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] Total [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 3-4-Other Long Term Liabilities: Others [Unsecured] Total 3-5-Long Term Provisions: S-Long Term Provisions: Provision for Employee Benefits 1,299	1	100%	share holding	
Surplus in statement of Profit and Loss: Balance as per last Balance Sheet Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year Balance as at the end of the year (87,946) Total 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] 124,176 124,17	l		rplus:	: 2-R
Less: Additional depreciation upon revision in useful lives of tangible assets [Refer Note-35] Add: Profit for the year Balance as at the end of the year Total 124,176 124,176	T			
Add: Profit for the year Balance as at the end of the year Total 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] Total 124,176 Total 124,176	(94	(88,937)	ast Balance Sheet	
Balance as at the end of the year Total (87,946) (87,946) : 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] Total [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] : 4-Other Long Term Liabilities: Others [Unsecured] Total 356 Total 5-Long Term Provisions: Provision for Employee Benefits 1,299		3,086	depreciation upon revision in useful lives of tangible assets [Refer Note-35]	
Total : 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] Total [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] : 4-Other Long Term Liabilities: Others [Unsecured] Total 356 356 356 356 357 Total 1,299	5,	4,077	ne year	
: 3-Long Term Borrowings: Loans and advances from Related Parties [Unsecured] [*] Total [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] : 4-Other Long Term Liabilities: Others [Unsecured] Total 356 Total 5-Long Term Provisions: Provision for Employee Benefits 1,299	(88)	(87,946)	e end of the year	
Loans and advances from Related Parties [Unsecured] [*] 124,176 Total 124,176 [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 124,176 : 4-Other Long Term Liabilities: 356 Total 356 Total 356 Total 1,299	(88,	(87,946)		Tota
Loans and advances from Related Parties [Unsecured] [*] 124,176 Total 124,176 [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 124,176 : 4-Other Long Term Liabilities: 356 Total 356 Total 356 Total 1,299	l		winge	. 3-1
Total [*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] : 4-Other Long Term Liabilities: Others [Unsecured] Total 356 356 356 356 370 370 370 370 370 370 370 37	132,	124.176		
[*] Details of Loans and Advances from Related Parties [Refer Note-33 for relationship] are as under: a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] : 4-Other Long Term Liabilities: Others [Unsecured] Total 356 Total : 5-Long Term Provisions: Provision for Employee Benefits	132,		and the second s	
a Cadila Healthcare Limited-Holding Company [Interest free loan without specific repayment terms] 124,176 124,176 124,176 124,176 1356 Total 1356 356 15-Long Term Provisions: Provision for Employee Benefits 1,299	1 192,		and Advances from Related Parties [Refer Note-33 for relationship] are as under:	
Others [Unsecured] 356 Total 356 S-Long Term Provisions: Provision for Employee Benefits 1,299	132,	124,176		
Others [Unsecured] 356 Total 356 : 5-Long Term Provisions: 1,299	l		Lishilitiaca	. 4. 0
Total 356 : 5-Long Term Provisions: Provision for Employee Benefits 1,299		356	ridomities:	
: 5-Long Term Provisions: Provision for Employee Benefits 1,299				
Provision for Employee Benefits 1,299				
		1 140		
	1,		Benefits	
1,299	1,	1,299		Total



Note: 5-Long Term Provisions-Continued:

Disclosure pursuant to Accounting Standard-15 [Revised] "Employee Benefits":

Defined benefit plan and long term employment benefit

A General description:

Leave wages [Long term employment benefit]:

The employees of the company are entitled to leave as per the leave policy of the company. The leave wages are payable to all eligible employees for each day of accumulated leave on death or on resignation or upon retirement on attaining superannuation age.

Gratuity [Defined benefit plan]:

The Company has a defined benefit gratuity plan. Every employee who has completed continuous services of five years or more gets a gratuity on death or resignation or retirement at 15 days salary [last drawn salary] for each completed year of service. The scheme is funded with an insurance company in the form of a qualifying insurance policy.

INR - Thousands

				Acc	t March 21		
		:	201E	<u> </u>	t March 31	2014	
			2015			2014	
В	Change in the assessment value of the	Med. Leave	Leave Wages	Gracuity	Med. Leave	Leave Wages	Gratuity
В	Change in the present value of the						
	defined benefit obligation:	1.00			•		
	Opening defined benefit obligation	18	1,006	1,322	21	1,084	1,228
	Interest cost	1	76	99	. 1	86	98
	Current service cost	21	129	171	1	118	157
	Past Service liability	235					
	Benefits paid	-	(95)	(77)		(57)	(36)
	Actuarial [gains]/ losses on obligation	(91)		99	(5)	(225)	(125)
	Closing defined benefit obligation	184	1,116	1,614	18	1,006	1,322
С	Change in the fair value of plan assets:			:			
	Opening fair value of plan assets	-	- 1	1,571	•	-	1,457
	Expected return on plan assets	-	-	130	-	-	134
	Contributions by employer	-	- 1	1.7	-	-	25
	Benefits paid	-	- ((77)	-	-	(36)
	Actuarial gains/ [losses]	<u> </u>	•	· (7)	-	-	. (9)
	Closing fair value of plan assets	-	•	1,634	-	-	1,571
	Total actuarial [losses]/ gains to be recognised	(91)	-	106	(5)	(225)	(116)
D	Actual return on plan assets:						
	Expected return on plan assets	-	-	130	-	-	134
	Actuarial [losses]/ gain on plan assets	ļ -	- ;	(7)	-	-	(9)
	Actual return on plan assets	:-	-		-	-	125
E	Amount recognised in the balance sheet:			·			
	Liabilities at the end of the year	184	1,116	1,614	18	1,006	1,322
	Fair value of plan Assets at the end of the year	; -	-	(1,634)	-	, ·	(1,571)
	Difference	184	1,116	(20)	18	1,006	(249)
	Unrecognised past Service cost	: :I =	-		-	-	-
	Liabilities / [Assets] recognised	:					
	in the Balance Sheet	184	1,116	(20)	18	1,006	(249)
F	Expenses / [Incomes] recognised in the			<u> </u>			<u> </u>
	statement of Profit and Loss:						
	Current service cost	21	129	171	1	118	157
	Past Service liability	235		-/-	_	110	137
	Interest cost on benefit obligation	1	76	99	1	86	98
	Expected return on plan assets	_ •	-	(130)		-	(134)
	Net actuarial [gains]/ losses in the year	(91)	_	106	· (5)	(225)	(116)
	Net expenses/ [benefits]	166	205	246	(3)	(21)	5
c	Movement in net liabilities recognised in		203	240	(3)	(21)	3
•	Balance Sheet:						
	Opening net liabilities	` 18	1,006	(249)	21	1 004	(220)
	Expenses as above [P & L Charge]	166	205	246		1,084	(229)
		100	4		(3)	(21)	(35)
	Employer's contribution		(95)	(17)	.	(57)	(25)
	Liabilities/ [Assets] recognised in the	404		(90)		1.005	(2.2)
	Balance Sheet	184	1,116	(20)	18	1,006	(249)



					- Thousands		
		4 4 .		As a	at March 31		
		1.	2015			<u>2014</u>	
		Med. Leave L	eave Wages	Gratuity	Med. Leave	Leave Wages	Gratuity
н	Principal actuarial assumptions as at Balan	ce sheet date:		:			
	Discount rate	7.80%	7.80%			9.10%	9.10%
	[The rate of discount is considered based on mar	ket yield on Gov	ernment Bo	n d s having cu	rrency and ten	ms consistence wi	th the
	currency and terms of the post employment bene	efit obligations]					
	Expected rate of return on plan Assets	0.00%	0.00%	8.75%	0.00%	0.00%	9.25%
	[The expected rate of return assumed by the Ins	urance company	is generally	based on the	ir Investment	patterns as stinula	ited
	by the Government of India]		- ,				
	Annual increase in salary cost	7.50%	7.50%	7.50%	7.50%	7.50%	7.50%
	[The estimates of future salary increases conside	red in actuarial v	aluation, tal		unt inflation, s	eniority promotion	n and
	other relevant factors such as supply and demand	d in the employn	nent market	1 :		ornority, promotion	i dita
I	The categories of plan assets as a % of total	al pian assets a	re:	•			
	Insurance Plan	0.00%		100.00%	0.00%	0.000/	100.000
J	Amount recognised in current and previous		0.0070	100.00 70	0.00%	0.00%	100.009
	and provides	Tour years.			As at Mars	L 21	
	Gratuity:	H	2011	2017	As at Marci		
	Defined benefit obligation	- - - - - - - - - -	2011	2012	2013	2014	2015
	Fair value of Plan Assets		891	949	1,228	1,322	1,6
	Deficit/ [Surplus] in the plan	:	890	1,140	1,436	1,571	1,6
			1	(191)	(208)	(249)	- (
	Actuarial Loss/ [Gain] on Plan Obligation		178	(104)	45	(125)	
	Actuarial Loss/ [Gain] on Plan Assets The expected contributions for Defined Benefit Plan		17	<u> </u>	-	(9)	
		1.		()		INR - Tho	
					<u> </u>		
e: 6-Trade	Pavables:					2015	2014
	Il and Medium Enterprises [*]	 				3- 1	·
Others					l		
Total	1				-	923	6,3
	The second secon			11	F	923	6,3
[*] Disclo	sure in respect of Micro, Small and Medium Enterp	oricos:			j		
	Principal amount remaining unpaid to any supplier		and		1		
	Interest due thereon	as at the year e	ena			•	-
	ATTACAGE CARE CATEFORD				I .		
r	Amount of interest paid by the Company in the com-	of coding to	Lb - 1401		ł	-	-
С	Amount of interest paid by the Company in terms	of section 16 of	the MSMED	Act, along wit	th the		-
	amount of the payment made to the supplier	r beyond the app	ointed day	during the yea	ar I		-
	amount of the payment made to the supplied Amount of interest due and payable for the period	r beyond the app I of delay in mak	oointed day o	during the year t [which have	ar I		-
	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur	r beyond the app I of delay in mak	oointed day o	during the year t [which have	ar I		-
D	amount of the payment made to the supplie Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act	r beyond the app I of delay in mak ring the period] I	pointed day or ing payment but without a	during the year t [which have	ar I		-
D E	amount of the payment made to the supplie Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid	r beyond the app I of delay in mak ring the period] I at the end of the	pointed day or ing payment but without a year	during the year t [which have	ar I		- - -
D E F	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and paya	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding	pointed day or ing payment out without of the payment out without or ingrees are years	during the year t (which have adding the	ar		-
D E F The a	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and payabove information has been compiled in respect of	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding parties to the ex	pointed day or ing payment out without a see year and years tent to which	during the year t (which have adding the	ar ee		- - - -
D E F The a	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and paya	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding parties to the ex	pointed day or ing payment out without a see year and years tent to which	during the year t (which have adding the	ar ee		- - - -
D F The a identi	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and pays bove information has been compiled in respect of fied as Micro, Small and Medium Enterprises on the	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding parties to the ex	pointed day or ing payment out without a see year and years tent to which	during the year t (which have adding the	ar ee		- - - -
D E F The a identi	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and payabove information has been compiled in respect of fied as Micro, Small and Medium Enterprises on the Current Liabilities:	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding parties to the ex	pointed day or ing payment out without a see year and years tent to which	during the year t (which have adding the	ar ee		- - - -
E F The a identi 2: 7-Other C Other Payal	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and payabove information has been compiled in respect of fied as Micro, Small and Medium Enterprises on the Current Liabilities:	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding parties to the ex	pointed day or ing payment out without a see year and years tent to which	during the year t (which have adding the	ar ee		-
E F The a identi 2: 7-Other C Other Payat Provis	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and payabove information has been compiled in respect of fied as Micro, Small and Medium Enterprises on the Current Liabilities: les: ion for Expenses	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding parties to the ex	pointed day or ing payment out without a see year and years tent to which	during the year t (which have adding the	ar ee	1,297	1,33
E F The a identi e: 7-Other C Other Payal Provis Payab	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and payabove information has been compiled in respect of fied as Micro, Small and Medium Enterprises on the Current Liabilities:	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding parties to the ex	pointed day or ing payment out without a see year and years tent to which	during the year t (which have adding the	ar ee	1,297 434	
E F The a identi 2: 7-Other C Other Payat Provis	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and payabove information has been compiled in respect of fied as Micro, Small and Medium Enterprises on the Current Liabilities: les: ion for Expenses	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding parties to the ex	pointed day or ing payment out without a see year and years tent to which	during the year t (which have adding the	ar ee	*	1
E F The a identi e: 7-Other (Other Payal Provis Payab Total	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and payabove information has been compiled in respect of fied as Micro, Small and Medium Enterprises on the Current Liabilities: bles: ion for Expenses le to Statutory Authorities	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding parties to the ex	pointed day or ing payment out without a see year and years tent to which	during the year t (which have adding the	ar ee	434	18
E F The a identi 2: 7-Other (Other Payal Provis Payab Total	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and payabove information has been compiled in respect of field as Micro, Small and Medium Enterprises on the Current Liabilities: bles: ion for Expenses le to Statutory Authorities	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding parties to the ex	pointed day or ing payment out without a see year and years tent to which	during the year t (which have adding the	ar ee	434	18
E F The a identi 2: 7-Other C Other Payal Provis Payab Total 2: 8-Short T Provision for	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and payabove information has been compiled in respect of fied as Micro, Small and Medium Enterprises on the Current Liabilities: bles: ion for Expenses le to Statutory Authorities	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding parties to the ex	pointed day or ing payment out without a see year and years tent to which	during the year t (which have adding the	ar ee	434	1,50
E F The a identi 2: 7-Other (Other Payal Provis Payab Total	amount of the payment made to the supplier Amount of interest due and payable for the period been paid but beyond the appointed day dur interest specified under the MSMED Act Amount of interest accrued and remaining unpaid Amount of further interest remaining due and payabove information has been compiled in respect of field as Micro, Small and Medium Enterprises on the Current Liabilities: bles: ion for Expenses le to Statutory Authorities	r beyond the app I of delay in mak ring the period] I at the end of the able in succeeding parties to the ex	pointed day or ing payment out without a see year and years tent to which	during the year t (which have adding the	ar ee	1,731	1,32 18 1,50

Note: 5-Long Term Provisions-Continued:



	th India Limited				
e: 9-Fixed Assets;	nancial Stateme	nts	····		
Tangible Assets:			INR-Thous	ands	
	Plant and	Furniture		Office	
	Equipment	and Fixtures	Vehicles	Equipment	Total
Gross Block:					
As at March 31, 2013	621	22,317	831	3,897	27,6
Additions	36	367	-	56	4
Disposals	(122)	-	-	- 1	(1
As at March 31, 2014	535	22,684	831	3,953	28,0
Additions	6	-	-	10	
Disposals	(456)	(1,753)	_	(182)	(2,3
As at March 31, 2015	85	20,931	831	3,781	25,6
Depreciation:			1	3,,011	20,0
As at March 31, 2013	504	13,032	263	2,072	15,8
Depreciation for the year	64	1,431	79	187	1,7
Disposals	(114)				(1
As at March 31, 2014	454	14,463	342	2,259	17,5
Adjusted to Retained Earnings [Refer Note-35]	39	1,609	- 1	1,438	3,0
Depreciation for the year [Refer Note-35]	13	1,553	122	40	1,7
Disposals	(442)	(1,574)		(173)	(2,1
As at March 31, 2015	64	16,051	464	3,564	20,14
Net Block:		10,031	,01	3,304	20,1
As at March 31, 2014	81	8,221	489	1,694	10,4
As at March 31, 2015	21	4,880	367	217	5,4
,		1,000	30/	21/	
		Nos.	Face	INR - Thou	sands
		[*]	Value	As at Man	ch 31
			r	2015	2014
e: 10-Non Current Investments:					
Long Term Investments [Valued at cost]:					<u>-</u>
Trade Investments in Equity Instruments			1	-	2,7
Total			r	-	2,7
Details of Trade Investments [Valued at cost]:	i		ľ	1	
	[Unqueted]:				
Investment in Equity Instruments of Subsidiary Companies	Loudnoted). I				
	[Onquoted].		ŀ	J	
Investment in Equity Instruments of Subsidiary Companies	[Onquoted].	250,000	10	2,500	2.5
Investment in Equity Instruments of Subsidiary Companies In fully paid-up equity shares of:	[Onquotea].	250,000 27,500	10 10	2,500 275	
Investment in Equity Instruments of Subsidiary Companies In fully paid-up equity shares of: Dialforhealth Greencross Limited	[Onquoted].	250,000 27,500		275	2
Investment in Equity Instruments of Subsidiary Companies In fully paid-up equity shares of: Dialforhealth Greencross Limited Dialforhealth Unity Limited	[Oriquoted].			· 1	2,5 2 2,7



tes: 11-Ong Term Loans and Advances: [Unsecured, Considered Good unless otherwise stated] Security Deposits Loans and Advances to Related Parties [*]: Considered good Considered doubtful [Refer Note-25] Less: Provision for doubtful advance [Refer Note-25] Less: Provision for doubtful advance [Refer Note-25] Other Loans and Advances: Balances with Custom/ Central Excise/ Sales Tax Authorities Advances recoverable in cash or in kind or for value to be received: Considered Good Considered Good Considered Good Considered Good Considered Good Considered Good Considered Goothful 255 Less: Provision for doubtful advances 265 Less: Provision for doubtful advances 275 Less: Provision for doubtful adv			
Comparison Com		INR - Thou:	sands
Unsecured. Considered Good unless otherwise stated		2015	2014
Security Deposits			
Loans and Advances to Related Parties (*): Considered good 200,000 2 201,500 2 201,500 2 201,500 2 201,500 2 201,500 2 201,500 2 200,000	[Unsecured, Considered Good unless otherwise stated]		***************************************
Considered doubtful [Refer Note-25] 200,000 2 Considered doubtful [Refer Note-25] 201,500 2 1,500 2 1,500 2 1,500 2 201,500 2	·	1,716	3
Considered doubtful (Refer Note-25) 1,500 201,500	Loans and Advances to Related Parties [*]:		
Considered doubtful [Refer Note-25] 1,500 201,590 1,50	Considered good	200,000	201
Less: Provision for doubtful advance [Refer Note-25] 1,500 200,000 2 200,000 2 2 2 2 2 2 2 2 2	Considered doubtful [Refer Note-25]	1,500	
Cites Provision for doubtful advance Refer Note-25 200,000 2		***************************************	201
Dither Loans and Advances: Balances with Custom/ Central Excise/ Sales Tax Authorities 78	Less: Provision for doubtful advance [Refer Note-25]	í 3	
Other Loans and Advances: Balances with Custom/ Central Excise/ Sales Tax Authorities Advance payment of Tax Advance payment of Sales on Interest Data Sales Sal			20:
Advance payment of Tax	Other Loans and Advances:	· 1	
Advance payment of Tax Advances recoverable in cash or in kind or for value to be received: Advances recoverable in cash or in kind or for value to be received: Considered Good Considered Good Considered Good Considered Good Considered Good Less : Provision for doubtful advances Total Total [*] Details of loans pursuant to Section 186(4) of Companies Act, 2013 (#): Name of the party and relationship with the party to whom loan given: A Subsidiary Company: a Dialforhealth Unity Limited [Interest free loan] [Refer Note-25] B Fellow Subsidiary Company: a B Isochem Pharmaceutical Industries Limited [Interest bearing loan] Total 200,000 200,000 201,500 20	Balances with Custom/ Central Excise/ Sales Tax Authorities	78	
Advances recoverable in cash or in kind or for value to be received: Considered Good Consider		1	1
Considered Good	Advances recoverable in cash or in kind or for value to be received:		_
Considered doubtful Cass Provision for doubtful advances Cass		127	
Less : Provision for doubtful advances Less : Provision for doubtful advances 128 127 128 127 128 127 128 129 127 129 120 120 120 120 120 120 120 120 120 120	Considered doubtful	1 1	
Less: Provision for doubtful advances 128 127 127 128 127 129 12			
127 805 7 7 7 7 7 7 7 7 7	Less: Provision for doubtful advances	1 1	
Total		***************************************	
[*] Details of loans pursuant to Section 186(4) of Companies Act, 2013 (#):	Total		200
Name of the party and relationship with the party to whom loan given: A Subsidiary Company: a Dialforhealth Unity Limited [Interest free loan] [Refer Note-25] B Fellow Subsidiary Company: a Biochem Pharmaceutical Industries Limited [Interest bearing loan] Total (#) Loans which are outstanding as at March 31, 2015. Notes: a All the above loans have been given for business purposes. b The loans are repayable within a tenure of 3 years. e: 12-Inventories: [The Inventory is valued at lower of cost and net realisable value] Stock-in-Trade 76,241 Total e: 13-Trade Receivables: [Unsecured, considered good] Outstanding for a period exceeding six months from the date they are due for payment Others - Considered good 1,689 e: 14-Cash and Bank Balances: Balances with Banks 3,460 Cash on Hand 553 Total e: 14-Cash and Bank Balances: [Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received 711 Total 711 712 713 714 715 716 716 717 716 717 717 717		202,521	206
A Subsidiary Company:			
a Dialforhealth Unity Limited [Interest free loan] [Refer Note-25] B Fellow Subsidiary Company: a Biochem Pharmaceutical Industries Limited [Interest bearing loan] 200,000 2 Total (#) Loans which are outstanding as at March 31, 2015. Notes: a All the above loans have been given for business purposes. b The loans are repayable within a tenure of 3 years. et 12-Inventories: [The Inventory is valued at lower of cost and net realisable value] Stock-in-Trade 76,241 Total et 13-Trade Receivables: [Unsecured, considered good] Outstanding for a period exceeding six months from the date they are due for payment Others - Considered good Total et 14-Cash and Bank Balances: Et 15-Short Term Loans and Advances: [Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received Total Total 16-Other Current Assets: Prepaid Expenses Frepaid Expenses Frepaid Expenses Frepaid Expenses Frepaid Expenses Frepaid Expenses Total T			
B Fellow Subsidiary Company: 200,000 2 200,000 2 201,500 2 2 201,500 2 2 201,500 2 2 2 2 2 2 2 2 2	· · · ·		
Biochem Pharmaceutical Industries Limited [Interest bearing loan] 200,000 2 201,500 2 201,500 2 201,500 2 201,500 2 201,500 2 201,500 2 201,500 2 201,500 2 201,500 2 201,500 2 201,500 2 201,500 2 2 201,500 2 2 201,500 2 2 201,500 2 2 201,500 2 2 201,500 2 2 201,500 2 2 201,500 2 2 201,500 2 2 201,500 2 2 201,500 2 2 201,500 2 2 201,500 2 2 2 2 2 2 2 2 2		1,500	1
Total			
(#) Loans which are outstanding as at March 31, 2015. Notes: a All the above loans have been given for business purposes. b The loans are repayable within a tenure of 3 years. E: 12-Inventories: [The Inventory is valued at lower of cost and net realisable value] Stock-in-Trade 76,241 Total 76,241 E: 13-Trade Receivables: [Unsecured, considered good] Outstanding for a period exceeding six months from the date they are due for payment Others - Considered good Total 1,689 E: 14-Cash and Bank Balances: E: 14-Cash and Bank Balances: [Unsecured, Considered Good] Advances with Banks 5,53 Total 5,555 Total 7,11 Total		······································	200
Notes: a All the above loans have been given for business purposes. b The loans are repayable within a tenure of 3 years. e: 12-Inventories: [The Inventory is valued at lower of cost and net realisable value] Stock-in-Trade 76,241 Total 761 101 101 101 101 101 101 101		201,500	201
a All the above loans have been given for business purposes. b The loans are repayable within a tenure of 3 years. E12-Inventories: [The Inventory is valued at lower of cost and net realisable value] Stock-in-Trade Total Total E13-Trade Receivables: [Unsecured, considered good] Outstanding for a period exceeding six months from the date they are due for payment Others - Considered good Outsdanding for a period exceeding six months from the date they are due for payment Others - Considered good 1,689 E14-Cash and Bank Balances: Balances with Banks Cash on Hand S553 Total E15-Short Term Loans and Advances: [Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received Total 711 Total E16-Other Current Assets: Prepaid Expenses 44 Total			
b The loans are repayable within a tenure of 3 years. e: 12-Inventories: [The Inventory is valued at lower of cost and net realisable value] Stock-in-Trade 76,241 Total 76,241 [Unsecured, considered good] Outstanding for a period exceeding six months from the date they are due for payment Others - Considered good 1,689 1,689 11-Cash and Bank Balances: 12-14-Cash and Bank Balances: 13-15-Short Term Loans and Advances: [Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received Total 711 Total 711 715-Other Current Assets:			
E: 12-Inventories: [The Inventory is valued at lower of cost and net realisable value] Stock-in-Trade 76,241 Total 77,1 Tot	a All the above loans have been given for business purposes.		
The Inventory is valued at lower of cost and net realisable value Stock-in-Trade Total Total	b The loans are repayable within a tenure of 3 years.		
The Inventory is valued at lower of cost and net realisable value Stock-in-Trade Total Page 13-Trade Receivables: [Unsecured, considered good] Outstanding for a period exceeding six months from the date they are due for payment Others - Considered good Total Page 14-Cash and Bank Balances: Balances with Banks Cash on Hand Stass Total Pist-Short Term Loans and Advances: [Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received Total Prepaid Expenses 44 Total	12 7		
Stock-in-Trade 76,241 76			
Total 76,241 13-Trade Receivables: [Unsecured, considered good] -	<u>-</u>	[]	
E: 13-Trade Receivables: [Unsecured, considered good] Outstanding for a period exceeding six months from the date they are due for payment Others - Considered good Total 1,689 E: 14-Cash and Bank Balances: Balances with Banks Cash on Hand 553 Total 2: 15-Short Term Loans and Advances: [Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received 711 Total 2: 16-Other Current Assets: Prepaid Expenses 44 Total 70tal			75
[Unsecured, considered good] Outstanding for a period exceeding six months from the date they are due for payment Others - Considered good Total 1,689	i otal	76,241	75
[Unsecured, considered good] Outstanding for a period exceeding six months from the date they are due for payment Others - Considered good Total 1,689	a: 13-Trade Pecaivables		
Outstanding for a period exceeding six months from the date they are due for payment Others - Considered good Total 1,689 1,68			
Others - Considered good 1,689 Total 1,689 2: 14-Cash and Bank Balances: 3,460 Eash on Hand 553 Total 4,013 2: 15-Short Term Loans and Advances: 2 [Unsecured, Considered Good] 711 Advances recoverable in cash or in kind or for value to be received 711 Total 711 2: 16-Other Current Assets: 44 Total 44 Total 44			
Total 1,689 1,689		-	
E: 14-Cash and Bank Balances: Balances with Banks Cash on Hand Total E: 15-Short Term Loans and Advances: [Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received Total E: 16-Other Current Assets: Prepaid Expenses Total Total Total Total Total Total Total	-		
Balances with Banks Cash on Hand Total 2: 15-Short Term Loans and Advances: [Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received Total 2: 16-Other Current Assets: Prepaid Expenses Total 3,460 553 4,013 711 711 711 711 711 711	. 4-601	1,689	
Balances with Banks Cash on Hand Total 2: 15-Short Term Loans and Advances: [Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received Total 2: 16-Other Current Assets: Prepaid Expenses Total 3,460 553 4,013 711 711 711 711 711 711	: 14-Cash and Bank Balances:		
Cash on Hand Total 15-Short Term Loans and Advances: [Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received Total 16-Other Current Assets: Prepaid Expenses Total Total 711 711 711 711 711 711 711 7		3.460	5
Total 4,013 2: 15-Short Term Loans and Advances: [Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received 711 Total 711 2: 16-Other Current Assets: Prepaid Expenses 44 Total 44	Cash on Hand	i ' I	3
2: 15-Short Term Loans and Advances: [Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received 711 Total 2: 16-Other Current Assets: Prepaid Expenses 711 44 711		***************************************	
[Unsecured, Considered Good] Advances recoverable in cash or in kind or for value to be received 711 Total 711 E: 16-Other Current Assets: Prepaid Expenses 44 Total 44		4,013	6
Advances recoverable in cash or in kind or for value to be received 711 Total 711 Tota	: 15-Short Term Loans and Advances:		
Total 711 711 711 711 711 711 711 711 711 71	[Unsecured, Considered Good]		
Total 711 E: 16-Other Current Assets: Prepaid Expenses 44 Total 44	Advances recoverable in cash or in kind or for value to be received	711	
Prepaid Expenses Total 44 44	Total		
Prepaid Expenses 44 Total 44		7.53	
Total 44	: 16-Other Current Assets:	<u></u>	
Total 44	Prepaid Expenses	44	
	Total		
e: 17-Contingent Liabilities and commitment [to the extent not provided for]			
		, ,	

Notes to the Financial Statements		
	INR - Thou	sands
	Year ended M	
	2015	2014
Note: 18-Revenue from Operations:		2011
Details of Gross Sales under broad heads:		
Sale of Pharmaceuticals Products	137,338	116,56
Total	137,338	116,56
Other Operating Revenues:		
Miscellaneous Income	693	1,50
Total	693	1,5
Note: 19-Other Income:		
Interest Income [Gross]	20,067	17,5
Total	20,067	17,5
Note: 20-Purchase of Stock-in-Trade:	<u> </u>	
Purchase of Stock-in-Trade:	122.400	112.2
Total	122,499 122,499	112,33
[*] It is not possible to furnish relevant information in respect of business carried on through Retail shops	144,499	112,3
in view of varied nature of items dealt in by the Company.		
in New or varied radice of items deale in by the company.		
lote: 21-Changes in Inventories:	<u> </u>	
Stock-in-Trade[*]	Ţ	
Stock at commencement	75,741	62,9
Less: Stock at close	76,241	75,7
Total	(500)	(12,7
[*] It is not possible to furnish relevant information in respect of business carried on through Retail shops		
in view of varied nature of items dealt in by the Company.		
Note: 22-Employee Benefit Expense:		
Salaries and wages	11,077	10,06
Contribution to provident and other funds [*]	633	6!
Staff welfare expenses	410	42
Total	12,120	11,14
[*] The Company's contribution towards the defined contribution plan	540	50
late 122 Finance Conti	<u> </u>	
Interest Expenses - Others		
Bank Commission and Charges	3	
Total	350	26
Total	353	28
lote : 24-Other Expenses:	<u> </u>	
Power & fuel	861	86
Rent	6,555	6,94
NCIIL	629	1,37
	336	47
Collaboration fees		18
	F	10
Collaboration fees Repairs to Others Insurance	178	1 94
Collaboration fees Repairs to Others Insurance Rates and Taxes [Excluding Taxes on Income]	178 190	1,86
Collaboration fees Repairs to Others Insurance Rates and Taxes [Excluding Taxes on Income] Housekeeping Expenses	178 190 1,985	2,7
Collaboration fees Repairs to Others Insurance Rates and Taxes [Excluding Taxes on Income] Housekeeping Expenses Legal and Professional Charges	178 190 1,985 116	2,7 1
Collaboration fees Repairs to Others Insurance Rates and Taxes [Excluding Taxes on Income] Housekeeping Expenses Legal and Professional Charges Travelling Expenses	178 190 1,985 116 90	2,7 1
Collaboration fees Repairs to Others Insurance Rates and Taxes [Excluding Taxes on Income] Housekeeping Expenses Legal and Professional Charges Travelling Expenses Other Marketing Expenses	178 190 1,985 116 90 708	2,7: { 1: 88
Collaboration fees Repairs to Others Insurance Rates and Taxes [Excluding Taxes on Income] Housekeeping Expenses Legal and Professional Charges Travelling Expenses Other Marketing Expenses Freight and forwarding on sales	178 190 1,985 116 90 708 423	
Collaboration fees Repairs to Others Insurance Rates and Taxes [Excluding Taxes on Income] Housekeeping Expenses Legal and Professional Charges Travelling Expenses Other Marketing Expenses Freight and forwarding on sales Net Loss on Assets sold/ discarded	178 190 1,985 116 90 708 423 66	2,71 { 11 88 41
Collaboration fees Repairs to Others Insurance Rates and Taxes [Excluding Taxes on Income] Housekeeping Expenses Legal and Professional Charges Travelling Expenses Other Marketing Expenses Freight and forwarding on sales	178 190 1,985 116 90 708 423	2,7: { 1: 88



	INR - Tho	usands
Ī	Year ended I	March 31
ľ	2015	2014
ease term		
	•	
	129	124
	67	6.
_	5	
	201	19
	2,500	-
ch 31,		
	275	-
	2,775	-
ch 31,		
	1,500	
	4,275	
INP-Thousands	4 077	E 22:
		5,23:
	4 077	5,231
1		5,000,000
· •		3,000,000
		1.05
	0.52	1.05
	-	-
	-	-
	-	-
	-	-
tatement		
1.	7.184	8,315
	- /20-	0,515
	5,584	8,078
1		
	10,152	18,127
	t. The powith the cordance ease term ch 31, INR-Thousands INR-Thousands INR-Thousands Numbers INR INR INR	The powith the cordance ease term 129 67 5 201 131, 275 2,775 11,500 4,275 INR-Thousands INR-Thousands INR-Thousands INR-Thousands INR



Note: 32-Segment Information:

A Primary Business Segment: Retail Trading in medicines/ cosmetics/ toiletries and providing business auxiliary services

External Sales

Inter Segment sales

Total Revenue

b Result:

Segment Result

Unallocated Income [net of Unallocated Expenses]

Operating and Net (loss)/ gain from Ordinary Activities

c Other Information:

Assets

Liabilities

Capital expenditure

Depreciation

Non Cash expenses other than depreciation

BG	eogra	phical	segment:
----	-------	--------	----------


Geographically the total business is within India only.

C Notes:

- a The Company is organised into two main business segments, namely:
 - Trading in Medicines/ Cosmetics/ Toiletries.
 - Business Auxiliary Services

Segments have been identified and reported taking into account, the nature of products and services, the different risks and returns, the organisation structure, and the internal financial reporting systems.

- **b** Segment revenue in each of the above segments primarily includes sales and services in the respective segments.
- c Segment revenue, results, assets and liabilities include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.





Note: 33-Related Party Transactions:

Name of the Related Party and Nature of the Related Party Relationship:

Holding Company:

Cadila Healthcare Limited

Subsidiary Companies:

Dialforhealth Greencross Limited

Fellow Subsidiaries:

German Remedies Limited Zydus Wellness Limited

M/s. Zydus Wellness-Sikkim, a Partnership Firm

Liva Pharmaceuticals Limited Zvdus Technologies Limited

Biochem Pharmaceutical Industries Limited Zydus BSV Pharma Private Limited M/s. Zydus Healthcare, a Partnership Firm

Zydus Lanka (Private) Limited [Sri Lanka] Zydus Healthcare Philippines Inc. [Philippines] Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands]

ZAHL B.V. [the Netherlands] ZAHL Europe B.V. [the Netherlands] Bremer Pharma GmbH [Germany]

Etna Biotech S.R.L. [Italy]

Directors and their relatives:

Dr. Sharvil P. Patel Mr. V. K. Sharma

Mr. Harish Sadana

Dialforhealth Unity Limited

Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA] Zydus Healthcare (USA) LLC [USA]

Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA]

Zydus Healthcare S.A. (Pty) Ltd [South Africa] Simayla Pharmaceuticals (Pty) Ltd [South Africa] Script Management Services (Pty) Ltd [South Africa]

Zydus France, SAS [France]

Zydus Nikkho Farmaceutica Ltda. [Brazil] Zydus Pharma Japan Co. Ltd. [Japan] Laboratorios Combix S.L. [Spain]

Zydus Pharmaceuticals Mexico SA De CV [Mexico]

Zydus Pharmaceuticals Mexico Services Company SA De C.V.[Mexico]

Zydus Worldwide DMCC [Dubai] Zydus Discovery DMCC [Dubai]

Chairman

Director - Operations

Director

Enterprises significantly influenced by Directors and/ or their relatives:

Cadmach Machinery Company Private Limited MabS Biotech Private Limited

Zydus Infrastructure Private Limited Cadila Laboratories Private Limited Pripan Investment Private Limited Zest Aviation Private Limited

Zydus Hospitals (Vadodra) Private Limited Zydus Hospitals (Rajkot) Private Limited

Zydus Hospitals and Healthcare Research Private Limited

Western Ahmedabad Effluent Conveyance Company Private Limited Zandra Infrastructure LLP Zydus Hospital LLP

M/s. C. M. C. Machinery M/s. Cadam Enterprises

Zandra Herbs and Plantations LLP

The following transactions were carried out with the related parties in the ordinary course of business:

Details relating to parties referred to in items 33 - A [a, b & c]

Value of the Transactions [INR-Thousands]

Subsidiary/

Nature of Transactions **Holding Companies**

2015 Cadila Healthcare Limited 121 121 **Issue of Share Capital:**

Cadila Healthcare Limited Finance:

Rent Paid:

Interest Received:

Biochem Pharmaceutical Industries Limited

Inter Corporate Loans given:

Biochem Pharmaceutical Industries Limited

Inter Corporate Loans accepted:

Cadila Healthcare Limited

Inter Corporate Loans repaid:

Cadila Healthcare Limited **Outstanding:**

Payable:

Cadila Healthcare Limited

Receivable: Dialforhealth Unity Limited

Biochem Pharmaceutical Industries Limited

Fellow Subsidiaries Year ended March 31.

2014 2015

20,000 17,511

2014

200,000

1,500

200,000

8,000

124,176

132,176

1.500

200,000

1,500 200,000



Note: 33-Related Party Transactions:

Name of the Related Party and Nature of the Related Party Relationship:

Holding Company:

Cadila Healthcare Limited

Subsidiary Companies:

Dialforhealth Greencross Limited

Fellow Subsidiaries:

German Remedies Limited Zvdus Wellness Limited

M/s. Zydus Wellness-Sikkim, a Partnership Firm

Liva Pharmaceuticals Limited Zydus Technologies Limited

Biochem Pharmaceutical Industries Limited Zydus BSV Pharma Private Limited M/s. Zydus Healthcare, a Partnership Firm

Zydus Lanka (Private) Limited [Sri Lanka] Zydus Healthcare Philippines Inc. [Philippines] Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands]

ZAHL B.V. [the Netherlands] ZAHL Europe B.V. [the Netherlands] Bremer Pharma GmbH [Germany]

Etna Biotech S.R.L. [Italv]

Directors and their relatives:

Dr. Sharvil P. Patel Mr V K Sharma Mr. Harish Sadana

Dialforhealth Unity Limited

Zydus Pharmaceuticals (USA) Inc. [USA] Nesher Pharmaceuticals (USA) LLC [USA] Zydus Healthcare (USA) LLC [USA]

Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA]

Zydus Healthcare S.A. (Pty) Ltd [South Africa] Simayla Pharmaceuticals (Pty) Ltd [South Africa] Script Management Services (Pty) Ltd [South Africa]

Zydus France, SAS [France]

Zydus Nikkho Farmaceutica Ltda. [Brazil] Zydus Pharma Japan Co. Ltd. [Japan] Laboratorios Combix S.L. [Spain]

Zydus Pharmaceuticals Mexico SA De CV [Mexico]

Zydus Pharmaceuticals Mexico Services Company SA De C.V.[Mexico]

Zydus Worldwide DMCC [Dubai] Zydus Discovery DMCC [Dubai]

Chairman

Director - Operations

Director

Enterprises significantly influenced by Directors and/ or their relatives:

Cadmach Machinery Company Private Limited

MabS Biotech Private Limited

Zydus Infrastructure Private Limited Cadila Laboratories Private Limited Pripan Investment Private Limited

Zest Aviation Private Limited Zydus Hospitals (Vadodra) Private Limited Zydus Hospitals (Rajkot) Private Limited

Zydus Hospitals and Healthcare Research Private Limited

Holding Companies

Western Ahmedabad Effluent Conveyance Company Private Limited

Zandra Infrastructure LLP Zydus Hospital LLP M/s. C. M. C. Machinery M/s. Cadam Enterprises

Zandra Herbs and Plantations LLP

B The following transactions were carried out with the related parties in the ordinary course of business:

a Details relating to parties referred to in items 33 - A [a, b & c]

Value of the Transactions [INR-Thousands]

2015 2014 2015 2014

Rent Paid: Cadila Healthcare Limited 121

Issue of Share Capital:

Cadila Healthcare Limited

Finance:

Interest Received:

Nature of Transactions

Biochem Pharmaceutical Industries Limited

Inter Corporate Loans given:

Biochem Pharmaceutical Industries Limited

Inter Corporate Loans accepted:

Cadila Healthcare Limited **Inter Corporate Loans repaid:**

Cadila Healthcare Limited

Outstanding: Payable:

Cadila Healthcare Limited

Receivable: Dialforhealth Unity Limited

Biochem Pharmaceutical Industries Limited

Subsidiary/

Fellow Subsidiaries

Year ended March 31,

121

200.000

20,000 17,511

200,000

1,500

8,000

124,176

132,176

1,500

1,500





Note: 33-Related Party Transactions-Continued:

b Details relating to persons referred to in Note 33-A [d] above:

INR - Thousands Year ended March 31

2015

2014

Remuneration:

Mr. V. K. Sharma

2,352

2,003

As at March 31

2014

Outstanding remuneration payable:

Mr. V. K. Sharma

There are no transactions with parties referred to in Note 33-A [e]

2015 158 151

Note: 34-Deferred Tax:

The Company has unabsorbed depreciation as well as carried forward losses under tax laws, resulting in to deferred tax assets. However, considering principle of prudence, deferred tax assets are not recognised in absence of virtual certainty supported by convincing evidence that sufficient future taxable income will be available against which such deferred tax assets can be realised.

Note : 35

Effective from April 1, 2014, the Company has started providing depreciation on tangible assets on "straight line method" over the revised remaining useful lives of the tangible assets in alignment with useful lives prescribed in Schedule II to the Companies Act, 2013. Consequently, the depreciation charge for the year ended March 31, 2015 is lower by Rs. 10 Thousands. Further, an amount of Rs. 3,086 Thousands has been recognised in the opening balance of retained earnings which relate to the carrying amount of tangible assets whose revised remaining useful life was Nil as at April 1, 2014.

Note: 36

Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure.

Signatures to Significant Accounting Policies and Notes 1 to 36 to the Financial Statements

tweek K. Patel

As per our report of even date

For Mukesh M. Shah & Co.

Chartered Accountants

Firm Registration Number: 10662500

For and on behalf of the Board

Chandresh S. Shah

Partner

Membership Number: 042132

Ahmedabad, Dated: 12 05 2015

Chief Financial Officer

Urt A. Kadakia Company Secretary

Director - Operation